Asahi Kasei Life Science Acquires License for Novel Antibody-Drug Conjugate Technology from The Noguchi Institute

Asahi Kasei Life Science has acquired the license rights for a novel antibody-drug conjugate (ADC) technology from The Noguchi Institute. This modality enables precise control over the drug-to-antibody ratio and attachment site of single- and dual-payload ADCs, representing a major breakthrough towa...